Cerus | CERS

Cerus traded at $3.25 this Friday February 3rd, decreasing $0.09 or 2.69 percent since the previous trading session. Looking back, over the last four weeks, Cerus lost 14.70 percent. Over the last 12 months, its price fell by 36.15 percent. Looking ahead, we forecast Cerus to be priced at 3.02 by the end of this quarter and at 2.73 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.25
Daily Change
-2.69%
Yearly
-36.15%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Terumo 3,814.00 53.00 1.41% -10.24%
Atrion 683.86 -10.72 -1.54% 8.21%
Cerus 3.25 -0.09 -2.69% -36.15%
Plus Therapeutics, Inc. 0.40 -0.01 -1.95% -57.09%
GRIFOLS 13.60 0.33 2.49% -10.26%
Haemonetics 87.13 0.76 0.88% 86.93%
Neogen 20.29 -0.81 -3.84% -42.80%
NuVasive 48.12 0.43 0.90% -4.09%
OraSure Technologies 5.47 -0.12 -2.15% -40.02%
Quidel 89.70 -1.76 -1.92% -9.27%
Rockwell Medical 1.91 -0.09 -4.50% 375.12%
Sientra 1.93 -0.12 -5.85% -28.78%
STAAR Surgical 77.97 -1.37 -1.73% 5.18%
Utah Medical Products 94.12 -2.35 -2.44% 0.38%
Meridian Bioscience 33.97 0 0% 62.93%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
US2000 1986 -15.69 -0.78% -0.84%

Cerus
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.